Our experimental work in mice has suggested that most, if not all, CD4+ T-cell specificities recognizing autoantigenic epitopes expressed by the target tissue of a given autoimmune disease can be re-programmed into Tr1 cells in vivo via pMHCII-NP therapy. The gene discussed is CD4; the disease is autoimmune disease.